The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter

Affiliations

• ¹ Cancer Pharmacology Lab, AIRC Start-UP Unit, University of Pisa, Pisa, Italy. Instituto de Tecnologias Biomedicas, Center for Biomedical Research of the Canary Islands, University of La Laguna, La Laguna, Spain.
• ² Cancer Pharmacology Lab, AIRC Start-UP Unit, University of Pisa, Pisa, Italy.
• ³ Department of Medical Oncology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands.
• ⁴ Department of Modern Sciences and Technologies and Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
• ⁵ Division of General and Transplant Surgery, University of Pisa, Pisa, Italy.
• ⁶ Cancer Pharmacology Lab, AIRC Start-UP Unit, University of Pisa, Pisa, Italy. Department of Medical Oncology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands. elisa.giovannetti@gmail.com e.giovannetti@med.unipi.it.